CraigSConoscentiMDFCCP, ATSF
Pulmonology • Seattle, WAInterstitial Lung Diseases, Restrictive Lung Disease
Sr. VP, Clinical Development Avalyn Pharma, Inc
Dr. Conoscenti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Sr. VP, Clinical Development
Avalyn Pharma, Inc
Seattle, WA 98101Phone+1 203-482-3219- Is this information wrong?
Education & Training
Norwalk HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 1985 - 1987
Hackensack University Medical CenterChief Residency, Internal Medicine, 1984 - 1985- Hackensack University Medical CenterResidency, Internal Medicine, 1982 - 1984
New York-Presbyterian Brooklyn Methodist HospitalInternship, Internal Medicine, 1981 - 1982
St. George's University School of MedicineClass of 1981
Certifications & Licensure
CT State Medical License 1985 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization.David Singer, Benjamin Chastek, Andrew Sargent, Jonathan C Johnson, Sharash Shetty, Craig Conoscenti, Elana J Bernstein> ;BMC Pulmonary Medicine. 2023 Sep 9
- 1 citationsBurden of illness in progressive fibrosing interstitial lung disease.David Singer, Lindsay G S Bengtson, Craig S Conoscenti, Amy J Anderson, Lee Brekke, Sharash S Shetty, Kevin K Brown> ;Journal of Managed Care & Specialty Pharmacy. 2022 Aug 1
- 3 citationsClaims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.David Singer, Lindsay G S Bengtson, Craig S Conoscenti, Marianne Laouri, Sharash S Shetty, Amy J Anderson, Kevin K Brown> ;Annals of the American Thoracic Society. 2022 Jul 1
- Join now to see all
Journal Articles
- Stability or Improvement in Forced Vital Capacity with Nintedanib in Patients with IPFKevin R Flaherty, Craig S Conoscenti, The European Respiratory Journal
Press Mentions
American Lung Association Announces New Support for Landmark Lung Health Cohort StudyJune 15th, 2021- Study Analysis Available During ATS 2021 Supports Long-Term Treatment with Ofev® in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseMay 14th, 2021
- 1st Patient Enrolled in Trial Testing Ofev on Post-COVID-19 PFNovember 23rd, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
